<< Call to speed access to innovative advances for all breast cancer patients | Smokers assume false sense of safety from ads for low nicotine cigarettes >>
Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Finnish | עִבְרִית | Русский | Svenska | Polski

Sodium hyaluronate shown to help chronic shoulder pain

Published on March 28, 2006 at 5:19 AM · No Comments

After the rise in safety concerns surrounding Vioxx and other Cox-2 inhibitors, people suffering from chronic shoulder pain were left with just two therapy options at opposite extremes - take Advil, or have surgery.

But a new study from Columbia University Medical Center shows that sodium hyaluronate, a drug that is FDA-approved for osteoarthritis of the knee, is also effective for shoulder pain.

The study was presented today at the American Academy of Orthopaedic Surgeons annual meeting in Chicago by Theodore Blaine, M.D., assistant professor of orthopaedic surgery at Columbia University Medical Center and an attending surgeon at NewYork-Presbyterian Hospital.

The study showed that in patients with osteoarthritis of the shoulder, sodium hyaluronate was effective in reducing chronic pain by nearly 50 percent. The results were comparable to the 1998 study that led the FDA to approve the drug's use in treating knee pain. The FDA is currently reviewing the results in shoulder pain.

"Chronic shoulder pain is a common problem that can not adequately be treated with existing FDA-approved therapies," said Dr. Blaine, who was the principal investigator of the study. "The results of the trial were very encouraging, and we hope will lead to this drug's approval as an effective therapy for thousands of suffering patients."

According to the National Institute of Musculoskeletal and Skin Diseases, shoulder problems account for about 1.5 million visits to orthopaedic surgeons annually. The pain can be caused by a variety of problems, including osteoarthritis or rotator cuff tears.

Sodium hyaluronate is a vital building block of normal cartilage. It is marketed under the name Hyalgan by Sanofi Aventis.

All of the patients in the study had previously tried nonsurgical clinical interventions - including physical therapy, at least one steroid injection, and various oral pain medications - but the pain persisted. At the beginning of the study patients received an x-ray of the shoulder to confirm the diagnosis of osteoarthritis and rule out fractures or other exclusionary criteria, as well as an MRI to diagnose soft tissue and bony pathology or a tear in the rotator cuff.

Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.



  Country flag

biuquote
  • Comment
  • Preview
Loading